IOP and medications decrease with sustained release bimatoprost implant
Real-world outcomes for treatment with sustained release bimatoprost implant (Durysta, Allergan) demonstrated lower topical glaucoma medication use while maintaining IOP in a diverse patient population, according to a study presented at ASCRS 2021 Annual Meeting. Certain subsets of patients, including those with higher corneal hysteresis, may have a more favorable outcome.
The retrospective review of glaucoma patients evaluated the efficacy and safety of the implant in a multi-center private practice setting with follow-up data (including number of topical medications) at 1 day, 1 week, 1 month, 3 months, 6 months and beyond. Endpoints included the IOP lowering through Week 12 and the percentage of patients achieving ≥20% through ≥40% IOP lowering.
The researchers reviewed results from 73 eyes from 44 patients (preop IOP of 22.62 mm Hg and preop glaucoma medications of 1.96). Follow up results: at 2 weeks, IOP was 20.54 mm Hg/1.71 glaucoma medications. At 6 weeks post implant, IOP decreased to 19.87 mm Hg/1.43 glaucoma medications. At 12 weeks IOP was 19.73 mm Hg/1.52 glaucoma medications. At 15 weeks, IOP was 19.90 mm Hg /1.15 glaucoma medications. Ten patients had further intervention during the study period, including 8 that had a corneal hysteresis that was less than 9.0 at the time of the injection, and 1 did not have corneal hysteresis recorded prior to injection.
Greenwood MD. Real world experience and outcomes with sustained release bimatoprost implant. Presented at: ASCRS 2021 Annual Meeting.